UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction of |
| (Commission File Number) |
| (IRS Employer |
incorporation) |
|
|
| Identification No.) |
| ||
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (
(Former name or former address, if changed since last report)
Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
| |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
| |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
| |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 12, 2021, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2021. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
In addition, the Company is furnishing a copy of an earnings presentation (the “Presentation”) that the Company intends to use, in whole or in part, in one or more meetings with investors, including a webcast on November 15, 2021. A copy of the Presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.
The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description |
Press Release issued November 12, 2021 (furnished pursuant to Item 2.02). | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
| Sanara MedTech Inc. |
| |
|
|
|
|
Date: November 12, 2021 | By: | /s/ Michael D. McNeil |
|
|
| Name: Michael D. McNeil |
|
|
| Title: Chief Financial Officer |
|
3 |
EXHIBIT 99.1
Sanara MedTech Inc. Announces Third Quarter 2021 Results and Business Update
FORT WORTH, TX / ACCESSWIRE / November 12, 2021 / Sanara MedTech Inc.
Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today its strategic, operational and financial results for the quarter ended September 30, 2021.
Ron Nixon, Sanara’s Executive Chairman, stated, “In the third quarter, Sanara continued to execute on its comprehensive wound and skin care strategy by gaining new hospital approvals for its surgical products, selling products into new facilities, executing an agreement and launching a pilot for WounDerm in the home health vertical, and adapting our EMR to the home health vertical. Our sales for the quarter were impacted by the COVID-19 Delta variant surge in key markets in Texas and the Northeast, which limited elective procedures during the quarter. As with previous surges, we believe that the majority of procedures that were not performed due to COVID-19 concerns in Q3 were postponed and will ultimately be performed at a later date.”
Third Quarter 2021 Strategic Highlights
Third Quarter and Nine Months Consolidated Financial Results
| · | Revenues. For the three months ended September 30, 2021, we generated revenues of $5,823,942 compared to revenues of $4,306,324 for the three months ended September 30, 2020, representing a 35% increase from the prior year period. For the nine months ended September 30, 2021, revenues totaled $17,110,511 compared to revenues of $10,797,838 for the nine months ended September 30, 2020, representing a 58% increase from the prior year period. The higher revenues in 2021 were primarily due to increased penetration of surgical wound care products by our sales force additions last year and our continuing present strategy to expand our independent distribution network in both new and existing U.S. markets. Revenues for the third quarter of 2021 were impacted by the response to the COVID-19 Delta variant. |
|
|
|
| · | Cost of goods sold. Cost of goods sold for the three months ended September 30, 2021, was $517,611, compared to cost of goods sold of $447,935 for the three months ended September 30, 2020. Cost of goods sold for the nine months ended September 30, 2021 was $1,528,449, compared to cost of goods sold of $1,126,798 for the nine months ended September 30, 2020. The increase over the prior year period was primarily due to higher sales volume. |
|
|
|
| · | Selling, general and administrative expenses. SG&A expenses for the three months ended September 30, 2021, were $6,920,105, as compared to $5,072,402 for the three months ended September 30, 2020. SG&A expenses for the nine months ended September 30, 2021, were $18,891,979 compared to SG&A expenses of $13,632,967 for the nine months ended September 30, 2020. The higher SG&A expenses in 2021 were primarily due to increased selling costs resulting from sales force expansion and operational support, higher sales commission expense as a result of higher product sales, and the addition of the Rochal Industries, LLC workforce effective July 1, 2021. Direct sales and marketing costs represented approximately 70% of the higher SG&A costs incurred in 2021. As part of our strategy to expand our sales reach in new and existing markets, we employed ten additional field sales managers since September 30, 2020. As of September 30, 2021, we had a total of 29 field sales managers. |
|
|
|
| · | Net income / loss. We had a net loss of $2,047,861 for the three months ended September 30, 2021, compared to net loss of $1,208,123 for the three months ended September 30, 2020. The higher net loss in the third quarter of 2021 was primarily due to higher SG&A expenses which were approximately $1.8 million higher than prior year, partially offset by higher third quarter gross profit which was $1.4 million higher than the same period in 2020. Third quarter 2021 depreciation, amortization, and other expenses collectively were approximately $0.4 million higher compared to prior year. For the nine months ended September 30, 2021, we had a net loss of $4,437,210, compared to net loss of $4,178,692 for the nine months ended September 30, 2020. The higher net loss for the three and nine months ended September 30, 2021 was primarily due to higher SG&A expenses, partially offset by higher revenues. The higher SG&A expenses in 2021 were primarily driven by increased selling costs as a result of sales force expansion and higher sales commissions due to higher product sales. |
Sanara will host a conference call on Monday, November 15, 2021, at 9:00 a.m. Eastern Time. The toll-free number to call for this teleconference is 888-506-0062 (international callers: 973-528-0011) and the access code is 337574. A telephonic replay of the conference call will be available through Monday, November 29, 2021, by dialing 877-481-4010 (international callers: 919-882-2331) and entering the replay passcode: 43371.
A live webcast of the conference call will be available under the Investor Relations section of the Company’s website, www.SanaraMedTech.com. A one-year online replay will be available after the conclusion of the live broadcast.
About Sanara MedTech Inc.
With a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets, distributes, and develops wound and skincare products for use by physicians and clinicians in hospitals, clinics, and all post-acute care settings and is seeking to offer wound care and dermatology virtual consultation services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX® Surgical Activated Collagen®, FORTIFY TRGTM Tissue Repair Graft and FORTIFY FLOWABLETM Extracellular Matrix to the surgical markets as well as the following products to the wound care market: BIAKŌS™ Antimicrobial Skin and Wound Cleanser, BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS™ Antimicrobial Skin and Wound Irrigation Solution and HYCOL™ Hydrolyzed Collagen. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement, and cell compatible substrates. The Company believes it has acquired the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skincare for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of the healthcare industry. For more information, visit SanaraMedTech.com.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “anticipate,” “believes,” “contemplates,” “continue” “could,” “estimates,” “expect,” “intend,” “may,” “plan,” “potential” “predicts,” “preliminary,” “project,” “seek,” “should,” “target,” “will,” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the development of new products and expansion of the Company’s business in telehealth and wound care. These items involve risks, contingencies and uncertainties such as Sanara’s ability to retain key employees, uncertainties associated with the development and process for obtaining regulatory approval for new products, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Contact:
Callon Nichols, Director of Investor Relations
713-826-0524
CNichols@sanaramedtech.com
EXHIBIT 99.2
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
'M4O=.35C^VO$BK+NT++*69<*V&4 8'UY_0CDUM[:
M^Z.58-1ORRT_X.V^WD
DW/BBQM9H[FWEO'DAEDMUEB(*2^8^Q&;/W2
MNWD]/QIC:IXI M_L\=S."H(,NG&,RR;@#&XS^[4 Y#]^>3M^96N!V]%<99W7
MC'[3;R7/S0LT+21?9-I >9D=
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